Product Reports Resources Pricing Login Book a demo

SpringWorks Therapeutics

Biotech & Life Sciences · New York City, United States · Founded 2017 · IPO 2019

Clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways MoreLess

SpringWorks Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with rare diseases and cancer. The company employs a precision medicine approach, which means they tailor treatments based on the genetic and molecular profile of the disease. This approach aims to improve the efficacy and safety of treatments for underserved patient populations suffering from devastating conditions. SpringWorks operates in the biopharmaceutical market, targeting both rare diseases and oncology. Their business model involves acquiring, developing, and commercializing innovative therapies. Revenue is generated through the successful development and commercialization of these therapies, often in collaboration with other pharmaceutical companies. The company serves a niche market of patients with specific genetic profiles, offering them potentially life-changing treatments that are not widely available. SpringWorks is actively involved in clinical trials, including Phase 1b and 2 studies, to evaluate the efficacy and safety of their drug candidates. Keywords: precision medicine, biopharmaceutical, rare diseases, cancer, clinical trials, genetic profiling, oncology, drug development, underserved patients, innovative therapies.

Valuation $3.26B
Revenue $192M
Total funding $100–500M

Talent graph

SpringWorks Therapeutics's talent

Book a demo to see the people
Employees mapped 352 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 32 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

16 investors on SpringWorks Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 8 investors entered at this stage
Pfizer
Bain Capital
OrbiMed
LifeArc
Perceptive Advisors
ArrowMark Partners
Samsara BioCapital
GSK
Series B+ 8 investors entered at this stage
GSK
Perceptive Advisors
EcoR1 Capital
ArrowMark Partners
Deerfield
Samsara BioCapital
Boxer Capital
Invus

Global footprint

Where SpringWorks Therapeutics has talent and traffic

Workforce by country
5 countries with
team presence
🇺🇸 United States92.8%
🇩🇪 Germany4.6%
🇨🇭 Switzerland1%
🇮🇹 Italy0.7%
🇬🇧 United Kingdom0.7%
5 countries shown
Web traffic by country
14K monthly visits
across markets
🇺🇸 United States92.1%
🇮🇳 India9.3%
Top 2 markets shown

Patent intelligence

$26M patent portfolio · 58 active families

Estimated portfolio value
$26M
0.81% of market cap · 5.5× larger than top peer Repare Therapeutics ($5M)
58 active patent families
Where SpringWorks Therapeutics innovates Cancer researchCarcinosisDiseaseInternal medicineNeurofibra

Where SpringWorks Therapeutics concentrates vs peers

Each axis is a top-10 topic across SpringWorks Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about SpringWorks Therapeutics

An AI-synthesized read of the highest-engagement posts about SpringWorks Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SpringWorks Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.